CSIMarket Company Name, Ticker, Suppliers, else..
 
Meridian Bioscience Inc   (NASDAQ: VIVO)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 44
 Employees 850
 Revenues (TTM) (Millions $) 302
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 10

Meridian Bioscience Inc
Meridian Bioscience Inc.
is a US-based company that specializes in the development, manufacturing, and distribution of diagnostic test kits, reagents, and related products for the healthcare industry.
The company's main product lines include gastrointestinal, respiratory, and viral and parasitic infection diagnostic test kits, as well as molecular diagnostic tests.
Meridian Bioscience Inc.
was founded in 1976 and is headquartered in Cincinnati, Ohio.
The company's mission is to improve global human health by providing innovative and high-quality diagnostic solutions.
Meridian Bioscience Inc.
is a publicly traded company, listed on the NASDAQ stock exchange under the ticker symbol VIVO.
The company operates through two main segments: Diagnostics and Life Science.
The Diagnostics segment primarily focuses on the development, manufacturing, and distribution of diagnostic test kits for gastrointestinal, respiratory, and viral and parasitic infection diagnostics.
The Life Science segment focuses on providing molecular diagnostic reagents, including RNA and DNA extraction kits and fluorescent dyes for research and clinical applications.
Meridian Bioscience Inc.
serves customers in more than 70 countries worldwide, including hospitals, reference laboratories, research institutes, and physician offices.
The company has established partnerships with leading healthcare organizations and diagnostic companies to expand its product portfolio and to advance healthcare solutions.
In addition, the company has invested heavily in research and development activities to diversify its product offerings and to stay at the forefront of diagnostic innovation.
Overall, Meridian Bioscience Inc.
has developed a reputation as a trusted supplier of quality diagnostic products and as an innovator in the diagnostic industry.


   Company Address: 3471 River Hills Drive Cincinnati 45244 OH
   Company Phone Number: 271-3700   Stock Exchange / Ticker: NASDAQ VIVO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ENDV        100% 
• View Complete Report
   



Burzynski Research Institute Inc

The evolving business from the In Vitro and In Vivo Diagnostic Substances market the BZYR reported the fiscal time-frame ending first quarter of 2025, numbers

After the bellwethers in the In Vitro and In Vivo Diagnostic Substances industry, a number of overlooked businesses are publishing the respective numbers. BZYR mentioned it has clinched operating deficit of $-0.331451 million, for the first quarter of 2025.

Biomerica Inc

Compelling revenue by BMRA amid the third quarter of 2025

For the December to February 28 2025 span BMRA decreased a loss per share of $-0.06 per share compare to $-0.88 a year prior and earnings per share improved from $-0.48 per share from the prior reporting period. The revenue were up by 10.029 % to $1.12 million from $1.02 million in the corresponding reporting period a year prior and sequentially Revenue Tumbled by -31.601 % from $1.64 million.

Tnf Pharmaceuticals Inc

Tnf Pharmaceuticals Inc reported operating deficit in the first quarter of 2025

The investors did not hope for any changes at the business all over the January to March 31 2025 reporting cycle at the Tnf Pharmaceuticals Inc . But, they pay very near attention to the In Vitro and In Vivo Diagnostic Substances company's operating deficit which has been at $-2.471834 million, during the same period.

Aspira Women S Health Inc

Aspira Women S Health Inc declared an unusual accomplishment, all along the most recent fiscal period

The In Vitro and In Vivo Diagnostic Substances company lost money at $-0.09 per share in the most recent fiscal period, although its revenue surged by 33.111 % to $3.20 million from the same quarter a year ago. AWHLs' flourishes in the first quarter of 2025, while literally all of companies in the In Vitro and In Vivo Diagnostic Substances industries are dealing with obstacles with the Diminishing transactions and experiencing diminishing revenue.

Nymox Pharmaceutical Corporation

In the fiscal fourth quarter of 2024 operating shortfall embodied enhancement to $-8.35 million, at the NYMX

While the October to December 31 2024 reporting season goes on, the most entities have reported their results. In the thick of it, have been several constituents of the In Vitro and In Vivo Diagnostic Substances sector. As well as, today, Nymox Pharmaceutical Corporation published operating shortfall of $-4.283 million, for the financial fourth quarter of 2024.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com